OSTEOproSPINE partner Eurice has recently joined forces with the European Patent Office (EPO) and the Licensing Executive Society International (LESI) for a special issue of “les Nouvelles”, the official journal of the LESI in the framework of the European IP Helpdesk. In OSTEOproSPINE, Eurice leads the Work Package ‘Innovation Management: Communication, Dissemination and Exploitation’.
The special issue looks at a number of successful technology transfer journeys demonstrating the importance of patents and other IP rights when translating research results into commercially successful products and services. Based on a new case study series jointly developed by the European Patent Office, the European Patent Academy and the European IP Helpdesk, the articles cover a range of economic sectors, countries, and types of technology transfer. Each article uses case studies to illustrate how strategic IP management facilitates critical collaborations and technology transfer (from lab to market), helps boost the market success of spin-offs and start-ups, and advances the business of IP globally in tangible ways.
In addition, the European IP Helpdesk contributed a piece specifically dealing with IP challenges and opportunities for SMEs in the context of EU-funded collaborative research projects. The expert article was written by Eurice's Jörg Scherer, Managing Director, and Stephanie Weber, Head of Communications & Marketing, in collaboration with the external expert Dr Eugene Sweeney, Director of Iambic Innovation Ltd. "We are delighted to have the opportunity to present this special issue of les Nouvelles in collaboration with LES International and the European Patent Office," says Jörg Scherer. "With this joint publication, the European IP Helpdesk further strengthens its relations with two key stakeholders in the IP and innovation landscape specifically increasing the service's outreach to the international technology transfer and licensing community through the cooperation with the LESI."
In OSTEOproSPINE, Eurice, together with the Coordinator UZSM, focus on developing a sound exploitation strategy for the project results and the IP management within the consortium. After the completion of a stage II clinical trial, the project results are not entering the market quite yet. However, a marketing authorisation of OSTEOproSPINE is envisaged in the long term, in order to help to re-establish spine stability and eliminate pain associated with degenerative disc disorders for millions of patients in Europe and the world.